A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma
- 10 September 2021
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (26), 2851-2854
- https://doi.org/10.1200/jco.21.01296
Abstract
No abstract availableThis publication has 50 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- The Inconvenience of Convenience Cohorts: Rhabdomyosarcoma and the PAX-FOXO1 BiomarkerCancer Epidemiology, Biomarkers & Prevention, 2012
- PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk StratificationJournal of Clinical Oncology, 2012
- Fusion Gene-Negative Alveolar Rhabdomyosarcoma is Clinically and Molecularly Indistinguishable from Embryonal RhabdomyosarcomaJournal of Clinical Oncology, 2010
- Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803Journal of Clinical Oncology, 2009
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of Diagnosis: A Report from the Children's Oncology GroupThe American Journal of Pathology, 2009
- Chronic Health Conditions in Adult Survivors of Childhood CancerThe New England Journal of Medicine, 2006
- Detection of the t(2;13)(q35;q14) and PAX3‐FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridizationGenes, Chromosomes and Cancer, 1995